Clinical trials: Cancer: Solid Tumors
Pediatric Solid Tumors
Development and Application of Intervention Program to Improve Mental Health and Quality of Life of Solid Tumor Survivors and Caregivers
The research team will assess the psychological abilities like cognitive(how you think and figure things out) and psycho-social(the well-being at the intersection of the internal workings and external experience) functions of…
- Trial name
- NCT06969742
- Testing
- Psycho-education and Psychological intervention_After cancer treatment, Psycho-education and Psychological intervention_In cancer treatment
- Where
- 3 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- National Cancer Center, Korea
Solid Tumors, Head and Neck Neoplasms
Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer
This is a Phase I multicenter, open-label, dose-escalation study of DTP348. DTP 348 is an oral dual drug with two mechanisms of action: 1.
- Trial name
- NCT02216669
- Testing
- DTP348
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Neoplasms
A Study of JNJ-1761981 in Participants With Solid Tumors
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981.
- Trial name
- NCT07525141
- Testing
- JNJ-1761981, Cetrelimab
- Where
- 4 sites in United States
- Volunteers
- 66 people
- Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
Advanced Solid Tumor, Lymphoma
Tumor Molecular Profiling in Early Phase Clinical Trials
Prospective, single centre, non-interventional exploratory research project that will be conducted on biological material and health-related personal data collected.
- Trial name
- NCT04510766
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- Oncology Institute of Southern Switzerland
Ewing Sarcoma, Sarcoma
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma
Background: Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted against some forms of cancer, but was never accepted as a treatment.
- Trial name
- NCT01610570
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with…
- Trial name
- NCT05975073
- Testing
- Anvumetostat, IDE397
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 53 people
- Sponsor
- Amgen
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Cancer, Adult Solid Tumor
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
- Conditions
- Cancer, Adult Solid Tumor, Lymphoma, Multiple Myeloma
- Trial name
- NCT03061305
- Where
- 40 sites in United States
- Volunteers
- 58,213 people
- Sponsor
- Strata Oncology
Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors
RATIONALE: Erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00033241
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- OSI Pharmaceuticals
Kidney Cancer, Melanoma (Skin)
Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer
- Trial name
- NCT00550654
- Testing
- questionnaire administration, 3-dimensional conformal radiation therapy, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer
This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer.
- Conditions
- Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis
- Trial name
- NCT05878405
- Testing
- Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse, Methylene Blue Oral Rinse
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Mayo Clinic
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Ewing Sarcoma, Ewing's Sarcoma Recurrent
Palbociclib + Ganitumab In Ewing Sarcoma
This research study is designed to study the combination of two drugs, palbociclib and ganitumab, as a potential treatment for Ewing sarcoma. The names of the study drugs involved in this study are: Palbociclib Ganitumab
- Trial name
- NCT04129151
- Testing
- Palbociclib, Ganitumab
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
GSAO in Treating Patients With Advanced Solid Tumors That Have Not Responded to Therapy
RATIONALE: GSAO may stop the growth of solid tumors by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of GSAO in treating patients with advanced solid tumors that have not…
- Trial name
- NCT01147029
- Testing
- angiogenesis inhibitor GSAO, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Cancer Research UK
Locally Advanced Solid Tumor, Metastatic Solid Tumor
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
This study evaluates the safety, tolerability and pharmacokinetics of HM95573 In combination with either cobimetinib or cetuximab in patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT03284502
- Testing
- HM95573, cobimetinib, HM95573, cetuximab
- Where
- 9 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Patients With Advanced Solid Tumors
A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced…
- Trial name
- NCT05370755
- Testing
- ICP-189
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Solid Tumor
Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
This is a multicenter, nonrandomized, open-label, safety, tolerability and pharmacokinetic (PK) study to determine the MTD and optimal dosing of Oratopo. No control group has been included.
- Trial name
- NCT03987685
- Testing
- Oratopo
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 10 people
- Sponsor
- Athenex, Inc.
Advanced Solid Tumors
A Study of HDM2024 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: Is the drug safe and tolerable ? Does the drug exhibit antitumor activity ?…
- Trial name
- NCT07539285
- Testing
- HDM2024
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.